Researchers in Korea and the United States have identified the principles of post-traumatic stress disorder (PTSD) treatment through animal experiments.
In the Ministry of Science and ICT (Ministry of Science and ICT), a research team led by Bo-Young Lee, a researcher at the Institute for Basic Science (IBS) Cognitive and Sociality Research Group, together with Yale University researchers in the United States, identified the mechanism of treatment for PTSD, and published an international brain science journal, Molecular Psychiatry. ) was published on the 14th.
Because an effective treatment for PTSD has not yet been found, psychiatric treatment such as cognitive behavioral therapy and drug treatment using antidepressants are often combined, but in this case, the improvement rate is only 50%.
Currently, the most active PTSD treatments are ketamine and rapastinel, of which ketamine is a psychotropic drug. Rapastinel cannot be administered orally and has a very short biological half-life of 7 minutes.
The research team focused on discovering the therapeutic mechanism of ‘NYX-783’, a similar NMDA receptor modulator, to compensate for the shortcomings of rapastinel. This drug is currently undergoing phase 2 clinical trials by U.S. bio company Aptinyx to develop it as a treatment for PTSD.
The research team explained that when NYX-783 was injected into an animal model (mouse) who experienced a fear situation 24 hours later, it was confirmed that the fear memory recurrence was suppressed.
Research Fellow Lee, the first author and corresponding author of the thesis, expected, “The results of this research will spur the development of PTSD treatments targeting the NMDA protein.”
(74)
